X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (35) 35
index medicus (32) 32
melanoma (31) 31
oncology (24) 24
male (20) 20
aged (16) 16
cancer (16) 16
middle aged (16) 16
melanoma - drug therapy (15) 15
dermatology (14) 14
female (14) 14
ipilimumab (14) 14
metastasis (14) 14
adult (12) 12
skin cancer (12) 12
skin neoplasms - drug therapy (12) 12
analysis (11) 11
care and treatment (11) 11
survival (10) 10
immunotherapy (9) 9
medicine & public health (9) 9
melanoma - pathology (9) 9
nivolumab (9) 9
skin (9) 9
treatment outcome (9) 9
antineoplastic agents - therapeutic use (8) 8
chemotherapy (8) 8
patients (8) 8
pembrolizumab (8) 8
retrospective studies (8) 8
antibodies, monoclonal - therapeutic use (7) 7
metastatic melanoma (7) 7
skin neoplasms - pathology (7) 7
tumors (7) 7
aged, 80 and over (6) 6
antibodies, monoclonal - adverse effects (6) 6
melanoma - secondary (6) 6
metastases (6) 6
therapy (6) 6
trial (6) 6
antibodies, monoclonal, humanized - therapeutic use (5) 5
carbon-dioxide (5) 5
cell lung-cancer (5) 5
chemistry, physical (5) 5
clinical trials (5) 5
complications and side effects (5) 5
diagnosis (5) 5
further section · weitere sektionen (5) 5
hematology, oncology and palliative medicine (5) 5
immunology (5) 5
methane (5) 5
monoclonal antibodies (5) 5
nickel-catalysts (5) 5
oxidation (5) 5
oxidation-reaction (5) 5
phase-ii (5) 5
prognosis (5) 5
research (5) 5
untreated melanoma (5) 5
antineoplastic agents - administration & dosage (4) 4
antineoplastic agents - adverse effects (4) 4
apoptosis (4) 4
autoimmunity (4) 4
carbon (4) 4
cell death (4) 4
co2 (4) 4
conversion (4) 4
engineering, chemical (4) 4
follow-up studies (4) 4
genetic aspects (4) 4
hydrotalcite (4) 4
immune checkpoint blockade (4) 4
kohlenstoff (4) 4
medical research (4) 4
melanoma - immunology (4) 4
methan (4) 4
mutation (4) 4
mutations (4) 4
neoplasm metastasis (4) 4
neoplasm staging (4) 4
nickelkatalysator (4) 4
pd-1 protein (4) 4
regression analysis (4) 4
risk factors (4) 4
young adult (4) 4
anionic clay (3) 3
antibodies (3) 3
antibodies, monoclonal - immunology (3) 3
blockade (3) 3
breast-cancer (3) 3
cancer research (3) 3
ctla-4 antigen - antagonists & inhibitors (3) 3
cutaneous melanoma (3) 3
development and progression (3) 3
efficacy (3) 3
flow (3) 3
germany (3) 3
health risks (3) 3
hydrotalkit (3) 3
immune-related adverse events (3) 3
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


JDDG - Journal of the German Society of Dermatology, ISSN 1610-0379, 04/2011, Volume 9, Issue 4, pp. 277 - 286
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 07/2012, Volume 30, Issue 21, pp. 2691 - 2697
Monoclonal antibodies directed against the immune checkpoint protein cytotoxic T-lymphocyte antigen-4 (CTLA-4; CD152)-ipilimumab and tremelimumab-have been... 
REGRESSION | METASTATIC MELANOMA | LYMPHOCYTE-ASSOCIATED ANTIGEN-4 | EFFICACY | ONCOLOGY | PHASE-II | MONOCLONAL-ANTIBODY | CTLA-4 | PATIENT | CANCER-IMMUNOTHERAPY | BLOCKADE | Stevens-Johnson Syndrome - immunology | Peripheral Nervous System Diseases - chemically induced | Skin Neoplasms - drug therapy | Humans | Ipilimumab | Antibodies, Monoclonal - adverse effects | Scleritis - chemically induced | Antineoplastic Agents - administration & dosage | Liver - immunology | Liver - drug effects | Antineoplastic Agents - adverse effects | Diarrhea - immunology | Pancreatitis - immunology | Scleritis - immunology | Mucous Membrane - drug effects | Colitis - immunology | Peripheral Nervous System Diseases - immunology | Antibodies, Monoclonal - immunology | Drug Eruptions - immunology | Skin - immunology | Melanoma - metabolism | Skin Neoplasms - pathology | Skin Neoplasms - immunology | Antineoplastic Agents - immunology | CTLA-4 Antigen - drug effects | Lymphatic Diseases - immunology | Antibodies, Monoclonal - pharmacokinetics | CTLA-4 Antigen - immunology | Pancreatitis - chemically induced | Melanoma - secondary | Chemical and Drug Induced Liver Injury - immunology | Pituitary Gland - immunology | Skin Neoplasms - metabolism | Lymphatic Diseases - chemically induced | Mucous Membrane - immunology | Antibodies, Monoclonal - administration & dosage | Melanoma - immunology | Uveitis - immunology | Melanoma - drug therapy | Uveitis - chemically induced | Pituitary Gland - drug effects | Skin - drug effects | Index Medicus
Journal Article
HAUTARZT, ISSN 0017-8470, 04/2019, Volume 70, Issue Suppl 1, pp. 72 - 74
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2017, Volume 35, Issue 15_suppl, pp. 9565 - 9565
Journal Article
Im Focus Onkologie, ISSN 1435-7402, 11/2017, Volume 20, Issue 11, pp. 39 - 42
Journal Article
Oncotarget, ISSN 1949-2553, 2018, Volume 9, Issue 40, pp. 26217 - 26225
After more than two decades with interferon alfa-2a and 2b (IFN) as the only approved drugs in the adjuvant setting for melanoma, new treatment approaches like... 
Patient preferences | Interferon | Melanoma
Journal Article
JDDG - Journal of the German Society of Dermatology, ISSN 1610-0379, 11/2013, Volume 11, Issue 11, pp. 1041 - 1047
Journal Article
Journal Article
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, ISSN 1610-0379, 11/2013, Volume 11, Issue 11, pp. 1041 - 1047
Journal Article
Journal Article
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, ISSN 1610-0379, 11/2013, Volume 11, Issue 11, pp. 1041 - 1047
Journal Article
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, ISSN 1610-0379, 11/2013, Volume 11, Issue 11, pp. 1041 - 1046
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.